185525-49-9

Basic information

• Product Name: 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one
• Synonyms: 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one;Spiro[indene-2,4-piperidin]-1(3H)-one hydrochloride;SPIRO[INDENE-2,4-PIPERIDIN]-1(3H)-ONE HCL
• CAS NO: 185525-49-9
• Molecular Formula: C13H15NO
• Molecular Weight: 201.2643
• Mol File: 185525-49-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one(185525-49-9)
• EPA Substance Registry System: 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one(185525-49-9)

Safety Data

• Hazardous Substances Data: 185525-49-9(Hazardous Substances Data)

Usage

General Description

1,3-dihydrospiro[indene-2,4'-piperidine]-1-one is a chemical compound with a unique molecular structure. It is a spiro compound containing an indene and piperidine ring system. 1,3-dihydrospiro[indene-2,4'-piperidine]-1-one has potential pharmaceutical significance and is known for its diverse biological activities. It has been studied for its potential as an antipsychotic and anxiolytic agent and has shown promising results in preclinical studies. Additionally, it has been explored for its potential as a therapeutic agent for various central nervous system disorders. Its unique structure and potential pharmacological properties make it an interesting compound for further research and development in the field of medicinal chemistry.

Upstream product

• 1228079-29-5 tert-butyl 1-oxo-1,3-dihydrospiro[indene-2,4’-piperidine]-1’-carboxylate 

Downstream Products

• 1207163-36-7 C₂₆H₂₆N₄O₃ 

Relevant articles and documents

Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine]

Cyclization of the benzoylpiperidine in lead compound 2 generated a series of novel and highly potent spiropiperidine-based stearoyl-CoA desaturase (SCD)-1 inhibitors. Among them, 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine] (19) demonstrated the most powerful inhibitory activity against SCD-1, not only in vitro but also in vivo (C57BL/6 J mice). With regard to the pharmacological evaluation, 19 showed powerful reduction of the desaturation index in the plasma of C57BL/6 J mice on a non-fat diet after a 7-day oral administration (q.d.) without causing notable abnormalities in the eyes or skin up to the highest dose (3 mg/kg) in our preliminary analysis.